Background: Breast cancer is a prominent cause of death among women worldwide. Recent studies have demonstrated that artemisinin (ART) displays anti-tumor activity. Using a mouse breast cancer model, we investigated the effects of ART in vitro and in vivo to determine how it influences the anti-tumor immune response. Methods: We measured the proliferation and apoptosis of 4T1 cells in vitro after ART treatment by MTT assay and FACS. To examine the effects of ART in vivo, tumor volumes and survival rates were measured in 4T1 tumorbearing mice. FACS was used to determine the frequencies of Tregs, MDSCs, CD4
Introduction
Breast cancer remains one of the leading causes of cancer-related death in women worldwide [1] . Although considerable progress has been made in treating breast cancer and prolonging patient survival, the cancer often reoccurs [2, 3] . Additionally, side effects from these treatments can have many adverse effects on the patients' quality of life [4, 5] . A greater understanding of breast cancer metastasis and discovery of new drugs are essential for the development of novel treatment strategies to eradicate breast cancer.
Artemisinin (ART) and its derivatives have long been used as antimalarials due to their efficacy and low toxicity [6] [7] [8] . However, recent studies have shown that ART derivatives possess profound anti-tumor activity as well. These studies have shown that ART inhibits the growth of numerous types of cancer cells, including breast, lung, prostate, melanoma, renal, gastric, and CNS cancer cells [9] [10] [11] [12] [13] . ART can also inhibit the growth of many drug-resistant cancer cell types [9] . Additionally, ART derivatives may also inhibit the growth of human tumor xenografts transplanted into mice [13] .
ART inhibits the proliferation of cancer cells through several mechanisms: 1) ART interacts with ferrous iron [14] , resulting in accumulation of reactive oxygen species (ROS) [15, 16] . ROS then weaken the integrity of the cell [17] , inducing cell cycle arrest [18] , apoptosis [19] , and autophagy [20] ; 2) ART inhibits angiogenesis by inhibiting the secretion of VEGF, VEGFR2, and KDR/flk-1 in tumors [21, 22] ; and 3) ART may affect signaling pathways and transcription factors associated with tumor growth, including the Wnt/β-catenin pathway, the AMPK pathway, nitric oxide signaling, NF-κB, CREBP, MYC/MAX, https://doi.org/10.1016/j.intimp.2019.01.041 Received 17 January 2019; Received in revised form 23 January 2019; Accepted 28 January 2019 T mTOR, and AP-1 [23] . However, the immune mechanisms affected by ART have not been described. In this study, we examined the effects of ART on anti-tumor immunity in vitro and in vivo to determine whether ART may be used to treat breast cancer.
Materials and methods

Cell lines and mice
Mouse 4T1 mammary carcinoma cells (Cell Bank of the Chinese Academy of Sciences, Shanghai, China) were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco, Life Technologies, Inc., USA) supplemented with 10% fetal bovine serum (FBS, Hyclone, USA), 100 mg/mL streptomycin, 100 U/mL penicillin, and 1 mM L-glutamine. Cells were grown at 37°C with 5% CO 2 and 100% humidity. Experiments were performed using cells in the exponential growth phase.
Six to eight-week-old female Balb/c mice were acquired from the Center of Zoology, Chinese Academy of Sciences, Shanghai Branch. The mice were housed under standard conditions for a week prior to the beginning of the experiment and given unimpeded access to food and water. All animal experiments were conducted under the guidelines of the Guide for the Care and Use of Laboratory Animals, China law of animal welfare. The experimental protocol was approved by the Committee on the Ethics of Animal Experiments of China National Institutes of Health (permit number GB 14923-2001).
Reagents
Artemisinin (ART, Sigma, St. Louis, MO, USA) was suspended in dimethylsulfoxide (DMSO, Solon, OH, USA) to create a stock solution of 10 mmol/L. The stock solution was stored at −20°C until use and further diluted in DMEM to its final concentration for in vitro use. For the in vivo experiments, ART was diluted with sterile PBS to 5 mg/mL before administration. All flow cytometry antibodies were purchased from BD Pharmingen (San Diego, CA, USA) unless otherwise indicated. A TGF-β enzyme linked immunosorbent assay (ELISA) kit was obtained from R&D Systems (Minneapolis, MN, USA), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Sigma (St. Louis, MO, USA), and RPMI 1640 with 10% FBS was purchased from Life Technologies (Bedford, MA, USA).
Establishment of the 4T1 breast cancer model
Sub-confluent 4T1 cells were harvested, washed once in serum-free media, and resuspended in PBS at a concentration of 5 × 10 5 cells/ 0.1 mL PBS. 0.1 mL of the cell suspension was then implanted into the abdominal mammary fat pad of female BALB/c mice subcutaneously. Once the tumor was palpable (5-7 days after implantation), the mice were randomized into either the control group (n = 7; intraperitoneal injection with 200 μl sterile PBS daily for 20 days) or the ART group (n = 10; intraperitoneal injection with 100 mg/kg ART dissolved in 0.2% DMSO daily for 20 days). Tumor volume was measured every 2-3 days using the following formula:
is the shortest diameter and d 2 is the longest diameter.
MTT assay
4T1 cells were cultured at a density of 5 × 10 3 cells per well in 96-well plates. After 24 h, ART was added to the cultures at the following concentrations: 0, 0.01, 0.1, 1, 10, and 100 μM in a final volume of 100 μL for 24, 48, or 72 h. Ten μL of 5 mg/mL MTT was then added to each well and incubated for 4 h at 37°C. One hundred μL of DMSO was then added for 10 min and incubated with light shaking. Optical densities (OD) at 570 nm were measured using a spectrophotometer. All experiments were repeated five times. Tumor cell proliferation rate is expressed as the percentage of cell growth inhibition using the following formula: % cells = (OD of ART-treated sample / OD of untreated sample) × 100%.
Apoptosis assay
4T1 cells were cultured in the presence or absence of ART (100 μM) for 48 h in 96-well plates at a concentration of 1 × 10 6 cells/mL. To detect apoptosis, the cells were stained using an Annexin-V Apoptosis Detection kit I (BD Biosciences) and subsequently evaluated by flow cytometry. The results were analyzed using FlowJo v7.6.2 and GraphPad Prism 6.0.1 software.
Flow cytometry
Spleens and tumors were excised from the 4T1 tumor-bearing mice. Single cell suspensions were produced by homogenizing the spleen samples, and the tumors were minced and subsequently digested with 500 U/mL collagenase type IV (Sigma) for 1 h at 37°C with agitation. The resulting single cell suspensions were suspended in RPMI 1640 with 10% fetal calf serum (FCS, Gibco, England).
To PerCP (clone 53-6.7, BD Biosciences), and anti-IFN-γ APC (clone XMG1.2, BD Biosciences) were added to the cells and incubated for 30 min. Cells were then fixed and permeabilized, and intracellular staining was performed using an anti-granzyme B PE antibody (clone NGZB, eBioscience). All staining reactions were performed in a final volume of 100 μl at 4°C. Data were acquired using a FACS Calibur flow cytometer (BD Biosciences, San Diego, CA, USA) and analyzed using FlowJo v7.6.2 software (Tree Star Inc., Ashland, OR, USA).
TGF-β ELISA
A commercial ELISA kit (R&D Systems, Minneapolis, MN, USA) was used to analyze TGF-β levels in the cell culture supernatants. All steps were performed according to the manufacturer's instructions, and OD values were measured at 450 nm using a microplate reader. A standard curve was generated using known concentrations of recombinant cytokines, and this was used to calculate the TGF-β concentrations of the samples.
RNA isolation and real-time RT-PCR
Trizol reagent (Invitrogen, Carlsbad, CA) was used to extract total RNA from excised tumors (~100 mg) per the manufacturer's instructions. The RNA was then quantified at 260 nm using a UV-VIS spectrophotometer (PYE-UNICAM, USA). To remove any contaminant genomic DNA, the RNA was treated with DNaseI and cDNA was synthesized using the PrimeScript™ RT reagent kit with gDNA Eraser kit (Takara, China). PCR was then performed using the cDNA as a template. Table 1 shows the specific oligonucleotide primers used for the PCR reaction. Quantitative PCR was performed on an ABI 7500 realtime PCR system (ABI, USA) using a SYBR® Premix Ex Taq™ reagent kit (Takara) according to the manufacturers' instructions. β-actin amplification served as an internal control. Gene expression was quantified using the 2 −ΔΔ CT method.
Statistical analysis
Results are presented as the mean ± standard deviation of three experiments. One-way ANOVA and two-tailed Student's t-tests were used to test for statistical significance. The Kaplan-Meier method was used to calculate survival analysis. P < 0.05 was considered statistically significant.
Results
ART inhibits proliferation of 4T1 cells
ART has been shown to considerably inhibit the proliferation of certain breast cancer cells, but this effect has not been demonstrated in 4T1 cells. Therefore, we performed an MTT assay to examine 4T1 cell proliferation after ART treatment. High doses (10 μM and 100 μM) of ART significantly inhibited the proliferation of 4T1 cells, beginning 24 h post treatment. Lower doses (0.01 μM, 0.1 μM, and 1 μM) of ART also inhibited proliferation, but not until 48 h post treatment. Furthermore, ART treatment also induced apoptosis of 4T1 cells, as 100 μM ART significantly increased the rate of tumor cell apoptosis (P < 0.01). Additionally, transforming growth factor β (TGF-β) levels in the supernatant significantly decreased following ART treatment (concentrations ranging from 1 to 100 μM, P < 0.001) (Fig. 1) . and Tregs (CD4 + CD25 + Foxp3 + ) in both the spleen and tumor (A and B). ⁎ P < 0.05 compared to the control group.
ART inhibits the growth of 4T1 breast cancer cells and prolongs the survival of 4T1 TB mice
To determine whether ART could suppress tumor development and enhance the survival of 4T1 TB mice, mice were given ART daily for 20 days. We found that the tumor volume in the ART group was reduced compared to that of the control group (Fig. 2B) . Similarly, the weight and size of the tumors were significantly decreased in the ART group (P < 0.001) compared to the control group (Fig. 2A) . No differences in body weights were seen between the two groups (Fig. 2C) . All the control mice died 28-45 days post 4 T1 cell inoculation. However, ART supplementation significantly extended the survival of 4T1 mice, with no deaths seen before 38 days post inoculation (P < 0.05; Fig. 2D ).
ART inhibits Treg and MDSC expansion in the spleen and tumor
CD11b
+ Gr-1 + MDSCs suppress immune responses in the tumor microenvironment and directly stimulate tumorigenesis, thereby promoting tumor development [24] . To assess whether ART treatment could inhibit the expansion of MDSCs, the frequencies of MDSCs in the spleens and tumors of 4T1 TB mice were analyzed by flow cytometry. We found that MDSC frequencies were significantly lower in both the splenic (P < 0.05) and tumor samples (P < 0.05) from ART-treated 4T1 TB mice compared to the control mice (Fig. 3A) .
Previous studies have shown that tumor-induced regulatory B cells (tBregs) can stimulate FoxP3 + Treg differentiation from resting nonregulatory CD4+ T cells, which suppresses host anti-tumor immunity and promotes metastasis [25] . Therefore, we also measured the frequencies of Tregs in the spleens and tumors of ART-treated and nontreated 4T1 TB mice. ART treatment significantly decreased the percentage of Tregs in TB mice (P < 0.05, Fig. 3B ), indicating that ART may inhibit immunosuppression in the tumor microenvironment. Various immune mediators in the tumor microenvironment, including cytokines and transcription factors, play crucial roles in inhibiting the progression of breast cancer. We used qRT-PCR to measure the relative mRNA expression levels of the transcription factors T-bet and FOXP3, and the cytokines IFN-γ, TNF-α, TGF-β, and IL-10 in the tumor tissues from 4T1 mice. As shown in Fig. 5 , expression of T-bet and the related pro-inflammatory cytokine IFN-γ, as well as TNF-α, increased after ART treatment (P < 0.01). TGF-β mRNA levels within the tumor significantly decreased after ART treatment (P < 0.01), while IL-10 levels did not change significantly. Expression of Foxp3, a transcription factor active in Tregs, also did not change significantly.
Discussion
As a leading cause of death in women, breast cancer remains difficult to control despite advances in treatment. Although many different approaches have been used to treat breast cancer, some of these treatments display significant toxicity and may lead to drug resistance. Thus, there is an urgent need for novel drugs which target cancer cells specifically without side effects. Aside from its anti-malaria activity, ART has shown strong anti-tumor activity in previous studies, especially in aggressive metastatic cancers [26] . In this study, we have demonstrated that reduced growth of breast cancer associated with ART is dependent upon the suppression of MDSCs and Tregs.
TGF-β is involved in the function and development of mammary epithelium and promotes cancer metastasis by inducing the epithelial to mesenchymal transition (EMT) of cancer cells [27, 28] . Increasing evidence suggests that TGF-β initially suppresses tumor growth, but that constitutive activation of TGF-β promotes tumor growth [29, 30] . Previous clinical studies have shown that excessive TGF-β levels in breast cancer patients are associated with metastases to the bone and regional lymph nodes [31] . In this study, we have demonstrated that TGF-β protein levels in the culture supernatant of 4T1 cells and mRNA levels in the tumor decrease after ART treatment.
MDSCs are a key immunosuppressive cell type and can suppress T cell-mediated anti-tumor immunity in breast cancer [32] . The suppressive abilities of MDSCs are closely related to their continuous expression of ARG-1, which metabolizes l-arginine [33] . In addition, MDSCs are involved in angiogenesis, invasion, and metastasis of cancer cells [34] . Another mechanism which suppresses tumor development is the overexpression of PD1 or CTLA-4 by Tregs [35] [36] [37] . CD4 + CD25 + Foxp3 + Tregs are a type of immune cell that play an important role in controlling the balance between pro-and anti-inflammatory immune responses [38, 39] . Foxp3, a transcription factor expressed in Tregs, is essential for the development and maintenance of Tregs [40] . IL-10 and TGF-β, as well as sustained expression of inhibitory CTLA-4, are key mediators of Treg-induced immunosuppression [41, 42] . Suppression of anti-tumor responses by Tregs was first demonstrated in mice treated with an anti-CD25 monoclonal antibody (clone PC61), which caused regression of the tumor [43] . In the 4T1 tumor model, Treg depletion results in accumulation of CTLs in the tumor [44, 45] . In the present study, ART supplementation significantly decreased the frequencies of MDSCs and Tregs in both the tumors and spleens, indicating that ART treatment can halt the immunosuppression caused by MDSCs and Tregs in 4T1 bearing mice. Anti-tumor immunity mediated by CTLs (CD8 + cytotoxic T cells) and CD4 + T helper 1 (Th1) cells inhibits cancer cell growth [46, 47] . nitrogen species (RNS) from macrophages, which leads to the destruction of cancer cells [48] . Th1 cells exert their anti-tumor effects through two major mechanisms: 1) they can directly kill tumor cells by engaging the TNF-related apoptosis-inducing ligand (TRAIL) or Fas/Fas ligand (FasL) pathways [49] or 2) they can help generate and enhance CTL responses [50] . We found that ART treatment significantly increased the frequencies of CTL and Th1 cells, as well as IFN-γ and TNF-α expression levels, in the tumor. In conclusion, ART inhibits breast cancer growth in vivo by promoting T cell activation as well as the suppression of Tregs and MDSCs in the tumor microenvironment.
